Post-COVID STSS Surge Tracks a Shift in Streptococcus pyogenes Lineages
Japan’s rebound in streptococcal toxic shock syndrome has a molecular signature. Nationwide surveillance during 2023 and 2024 linked the increase to a sharp expansion of emm1 Streptococcus pyogenes, with M1UK and M113SNPs pushing aside the older M1global lineage that had dominated earlier circulation. The signal matters because STSS is not a routine invasive infection; it is a rapidly progressive syndrome marked by shock and multiorgan failure, where delays in recognition can be fatal.
The study analyzed 919 isolates from laboratory-confirmed STSS cases reported across Japan over two years. Those isolates came from 1,477 reported cases, giving an overall coverage of 62.2%. Coverage varied by year, reaching 45.9% in 2023 and 68.4% in 2024. Even with incomplete capture, the lineage pattern was hard to miss: emm1 accounted for 470 of 919 isolates, or 51.1%, and its share rose markedly in 2024 after a policy shift that relaxed masking in March 2023.
A single sentence captures the epidemiologic turn: after COVID-era transmission barriers fell, invasive group A streptococcal disease climbed back.
Lineage Replacement Inside the emm1 Cluster
Within the emm1 subset, the investigators found three major lineage groups: M1UK in 234 isolates (49.8%), M113SNPs in 176 (37.4%), and M1global in 60 (12.8%). This represents a clear replacement pattern. Compared with 2019, when M1global represented more than 60% of emm1 isolates, the 2023–2024 collection showed M1UK rising from 44% to 51% and M113SNPs rising from 29% to 39%, while M1global fell from 26% to 11%.
The changes were not uniform across lineages. M1UK and M113SNPs each rose after mask relaxation, and the broader national curve for emm1-associated STSS climbed to 60–80 cases per month during January through June 2024. Other lineages such as emm89, emm81, and emm49 remained comparatively stable, which makes the emm1 expansion stand out as a driver rather than a background fluctuation. emm12 also increased, but the dominant story was the rise of emm1-derived strains.
The biological logic is plausible. Group A streptococci spread efficiently through close-contact environments, and the return of routine respiratory transmission opportunities in schools and communities likely reopened a pathway that had been dampened during COVID-era nonpharmaceutical interventions. Once transmission resumed, lineages with enhanced fitness could spread through susceptible populations and enter invasive disease chains.
speA and speC Profiles Point to Distinct Strain Behavior
The toxin gene pattern adds another layer. Among 470 emm1 isolates, 458 were speA positive. Most carried either speA alone or both speA and speC. M1UK was mainly speA-only, with 202 isolates in that category, or 86.3% of M1UK strains. M113SNPs behaved differently: 143 isolates, or 81.3%, carried both speA and speC. M1global was also mostly speA-only.
This matters because superantigen profiles shape the inflammatory response that drives STSS. Invasive disease emerges when bacterial virulence intersects with host susceptibility, and toxin expression can amplify the cytokine surge that contributes to shock, organ dysfunction, and death. The mixed speA/speC profile in M113SNPs may reflect a distinct pathogenic program, although the study was not designed to prove mechanism. Still, the molecular contrast between M1UK and M113SNPs makes simple lineage labeling less informative than it first appears.
Younger Patients and Higher Mortality in M113SNPs Cases
Clinical differences emerged alongside the genomic shifts. M113SNPs infections involved younger patients, with an average age of 58.3 years, and showed a mortality rate of 31.3%. For comparison, non-emm1 STSS cases had an average age of 62.7 years and a mortality rate of 23.2%. M1UK also affected younger patients, average age 54.9 years, but its mortality rate was 20.5%, similar to M1global at 20.0%.
The mortality signal for M113SNPs persisted in unadjusted comparisons. Age and sex distributions did not differ significantly between M113SNPs cases and non-emm1 cases, yet mortality remained higher in the M113SNPs group, with an odds ratio of 1.51 and a 95% confidence interval of 1.02 to 2.22. Age-stratified analysis sharpened the concern further: among patients 25 to 39 years old, the odds ratio for death was 5.00; among those 70 to 84 years old, it was 2.24.
Surveillance Relevance Extends Beyond One Country
Japan’s experience fits a broader pattern. Expansion of M1UK has already been reported in Europe, and the Japanese data show that M113SNPs deserves equal attention. The surveillance system that captured these findings is organized through the National Institute of Infectious Diseases and prefectural public health laboratories, with STSS notifiable under the Infectious Disease Control Law. Standardized methods, from emm genotyping to allele-specific PCR for lineage assignment, allowed the investigators to compare strains across regions and across time.
The public health value is straightforward. Lineage-level surveillance can reveal shifts in transmissibility and virulence before they are obvious at the bedside. Invasive streptococcal disease does not announce itself politely, and a rise in a strain associated with higher mortality has direct implications for empiric suspicion, outbreak monitoring, and laboratory capacity.
What the Dataset Can and Cannot Prove
The study’s limitations are substantial and should shape interpretation. Isolate coverage reached only 62% overall, and the analysis was restricted to STSS rather than all invasive group A streptococcal disease. The time window was limited, clinical data were incomplete, and the mortality analyses were unadjusted. Unmeasured factors such as underlying illness, treatment timing, or illness severity could have influenced the apparent association between M113SNPs and death.
Even so, the scale of the collection gives the findings weight. Nine hundred nineteen isolates across Japan provided a rare national view of a fast-moving pathogen population. The core message is not that one lineage has been definitively proven deadlier than another, but that emm1 has reasserted itself after COVID-era transmission restrictions eased, and M113SNPs now warrants close clinical and genomic attention. Continued surveillance is needed to track whether these lineages stabilize, expand further, or give way to newer variants in future Streptococcus pyogenes epidemics.